Chronic kidney disease (CKD) is common, harmful, and treatable. One of the major obstacles to the care of individuals with and at risk for CKD is the lack of sensitive and specific biomarkers to measure disease onset, progression, prognosis, and response to treatment. Our proposal to join the CKD Biomarker Consortium as a validation site for urinary biomarkers of CKD draws from our experience with discovery and validation of novel tubular injury biomarkers in preclinical and clinical settings as well as interactions with regulatory agencies such as the Food and Drug Administration. We propose bringing to the CKD Biomarker Consortium four cohorts with available urine samples to validate urinary biomarkers: 1) A kidney biopsy biospecimens bank from Brigham and Women's Hospital (N = 121 native and 78 allograft to date;enrollment 1 to 3 per week). 2) A kidney biopsy biospecimens bank of IgA nephropathy, lupus nephritis, renal vasculitis, and Chinese herbal nephropathy from our established collaboration with Peking University First Hospital (PUFH) in Beijing, China (N = 430;enrollment 7 per month);3) An epidemiological study on endemic (Balkan) nephropathy from the University of Zagreb School of Medicine (N = 1074;additional 500 to 700 in 2010);4) An observational cohort of lupus patients seen at the Brigham and Woman's Hospital Lupus Center (N=40 to date;enrollment expected to be ~300 withing 24 months). Our access to large and diverse cohorts of individuals with and at risk for CKD will provide ample statistical power to investigate the clinical utility of the following urinary biomarkers: kidney injury molecule-1 (KIM-1);N-acetyl-beta-D-glucosaminidase (NAG);neturophil gelatinase-associated lipocalin (NGAL);urinary L-type fatty acid binding protein (L-FABP);interleukin-18 (1L-18);urinary cystatin C;albumin;hepatocyte growth facmr (HGF);interferon-inducible protein (IP-10);and connective tissue growth factor (CTGF). We hypothesize that urinary biomarkers noninvasively predict histopathological findings on kidney biopsy, which are in turn predictive of CKD progression;and that urinary biornarkers are superior to conventional markers (serum creatinine and albuminuria) as predictors of CKD progression.

Public Health Relevance

Chronic kidney disease afflicts more than 11% of the United States population and is one of the most potent predictors of cardiovascular disease and all-cause mortality. The identification of clinically useful CKD biomarkers will improve the care of individuals with and at risk for CKD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK085660-04
Application #
8327652
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O1))
Program Officer
Kimmel, Paul
Project Start
2009-09-30
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
4
Fiscal Year
2012
Total Cost
$178,500
Indirect Cost
$91,649
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Leaf, David E; Body, Simon C; Muehlschlegel, Jochen D et al. (2016) Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery. J Am Soc Nephrol 27:3291-3297
Waikar, Sushrut S; Sabbisetti, Venkata; Ärnlöv, Johan et al. (2016) Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol Dial Transplant 31:1460-70
Mc Causland, Finnian R; Asafu-Adjei, Josephine; Betensky, Rebecca A et al. (2016) Comparison of Urine Output among Patients Treated with More Intensive Versus Less Intensive RRT: Results from the Acute Renal Failure Trial Network Study. Clin J Am Soc Nephrol 11:1335-42
Leaf, David E; Srivastava, Anand; Zeng, Xiaoxi et al. (2016) Excessive diagnostic testing in acute kidney injury. BMC Nephrol 17:9
Leaf, David E; Croy, Heather E; Abrahams, Sara J et al. (2015) Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. Crit Care 19:80
Fufaa, Gudeta D; Weil, E Jennifer; Nelson, Robert G et al. (2015) Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus. Nephrol Dial Transplant 30:599-606
Shinke, Haruka; Masuda, Satohiro; Togashi, Yousuke et al. (2015) Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 76:989-96
Antoine, Daniel J; Sabbisetti, Venkata S; Francis, Ben et al. (2015) Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury. Hepatology 62:591-9
Fufaa, Gudeta D; Weil, E Jennifer; Nelson, Robert G et al. (2015) Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 58:188-98
Hsu, Chi-Yuan; Ballard, Shawn; Batlle, Daniel et al. (2015) Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium. Clin J Am Soc Nephrol 10:894-902

Showing the most recent 10 out of 26 publications